Nanemiar (@Nanemiar) header
Nanemiar (@Nanemiar) profile picture
Joined November 2023
Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)Photo by Nanemiar (@Nanemiar)
Today, our partner Mercurna participated in LNPs Europe 2026 in Berlin, where the NANEMIAR project was presented to experts from across the RNA therapeutics and drug delivery community.
2
1
22
Thank you to Informa for the invitation and to everyone who joined the discussion. Collaboration and knowledge exchange are key to maximising NANEMIAR’s impact. #NANEMIAR #HorizonEurope #LNPsEurope #RNAtherapeutics #DrugDelivery #Innovation #Collaboration
4
The presentation showcased NANEMIAR’s efforts to advance innovative RNA-based therapies for congenital anemias, highlighting the challenge of targeted delivery beyond the liver.
1
7
🔬 4th NANEMIAR Consortium Meeting | Bilbao, Spain During the SEHH Congress (22–24 October), the NANEMIAR consortium held its 4th meeting to review project progress, discuss the latest results and coordinate next steps.
1
2
29
🤝 Thank you to all consortium members for their commitment and collaboration towards our shared research goals! #NANEMIAR #OCAILab #SEHH #Research #Hematology #Collaboration #Innovation
1
5
🏆 OCAI LAB has been selected for Best Presentation in Erythropathology at the SEHH meeting in Bilbao! 🙏 Thanks to the organising committee and to Drs Eduardo Salido, Salvador Payán and Miguel Blanquer for their contributions to NANEMIAR.
1
1
34
💙 Advancing research together! #OCAILab #NANEMIAR #SEHH
6
🩸 Blood has a lot to tell us about our health. Every sample and analysis brings us closer to better understanding diseases and opening new paths toward more effective treatments. Research is the key to understanding its stories. 🔬💡 #Nanemiar #MedicalResearch #Health #Science
🤖 Made with AI
19
🔬 NANEMIAR at the European Researchers’ Night 2026! On September 25, our team took part in this event in Murcia, bringing our research on congenital anemias closer to society.
1
1
6
115
A great opportunity to share science, raise awareness of patients’ challenges and highlight how biomedical research can contribute to new therapeutic strategies. 🩸✨ #EuropeanResearchersNight #NANEMIAR #BiomedicalResearch #CongenitalAnemias
1
2
15
🩸 DONATE BLOOD. SHARE LIFE For people living with congenital anemias, blood transfusions can be an essential part of their treatment. And behind every transfusion, there is a donor.
1
1
32
At NANEMIAR, we are working towards new therapeutic approaches based on mRNA and nanomedicine to improve red blood cell production and, in the future, reduce the need for transfusions. 🔬 Research is looking for new solutions. 🩸 Donations are helping patients today
1
1
20
Until new treatments become available, every donation matters. Donate blood. Give time. Give hope. Share life. ❤️ #nanemiar #donateblood #blooddonation #congenitalanemias #rarediseases #nanomedicine #nanopartículas #research #hematology #erythropoiesis #sciences #sharelife
8
☀️ Happy September! Today, we want to show you the whole world hidden inside a drop of blood 🩸🔬.
🤖 Made with AI
1
31
Although it may seem tiny, a drop of blood contains an enormous amount of information and essential elements for our body. In addition, blood is one of the most important biological samples we use in our laboratory, both to study diseases and to advance scientific research.
🤖 Made with AI
1
17
Can you imagine everything we can discover inside a single drop? 👀🩸 Join us to discover it! 🔬✨
🤖 Made with AI
8
New NANEMIAR Story! Meet Dr. Jurgen Dieker, CSO at Mercurna 🇳🇱, and discover his role in developing therapeutic mRNA and targeted LNP delivery systems. He shares his vision for mRNA therapies, the challenges of targeted delivery and what inspired him to co-found Mercurna. 🚀
1
31
In this new NANEMIAR interview, we spoke with Léa Girondier (CNRS), a researcher in the project, who shares her experience in the development of new therapeutic strategies for congenital anemias.
1
3
3
83
Throughout the conversation, she explains her role in conducting experiments using ex vivo and in vivo models, the technical challenges involved in optimizing protocols within complex biological systems, and the importance of validating results.
1
1
33
She also reflects on the potential of mRNA-based therapies to improve red blood cell production and their impact on patients with beta-thalassemia and other hereditary hematological diseases. Link to the interview: nanemiar.eu/nanemiar/news.js…
17